CERo Therapeutics Announces Listing on OTC Markets

Core Insights - CERo Therapeutics Holdings, Inc. continues to trade under the ticker symbol CERO on the OTC Markets, with no action required from investors [1] - The company is exploring options for an up-list to enhance liquidity and investor accessibility [1] - CEO Chris Ehrlich emphasized the company's commitment to maximizing shareholder value and advancing its clinical trials, particularly for CER-1236 in AML [2] Company Overview - CERo is focused on developing next-generation engineered T cell therapeutics for cancer treatment, integrating both innate and adaptive immunity [3] - The company's proprietary platform aims to redirect patient-derived T cells towards tumor cells using both adaptive and innate mechanisms, creating Chimeric Engulfment Receptor T cells (CER-T) [3] - CERo believes that CER-T cells may provide advantages over existing CAR-T therapies and could be effective for both hematologic malignancies and solid tumors [3] - Clinical trials for CER-1236, the lead product candidate, have been initiated for hematologic malignancies [3]